We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MMM:NYSE3M Company Analysis

Data as of 2026-03-10 - not real-time

$151.63

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

3M (MMM) is trading at $151.63, well below its 20‑day SMA of $164.94 and 50‑day SMA of $163.29, indicating short‑term weakness, but the RSI of 32.6 suggests the stock is oversold and could be poised for a bounce. Technical momentum remains mixed: the MACD histogram is negative and the signal is bearish, yet the computed trend direction is bullish and volume is increasing, supporting a potential near‑term rebound toward the $147.72 support level. Fundamentally, the company delivered an earnings beat in Q4 2025 with EPS of $1.83 versus expectations of $1.80, and the board has just declared a quarterly dividend of $3.12, yielding 2.03% with a payout ratio under 50%, indicating dividend sustainability.
However, valuation metrics raise caution: the DCF‑derived fair value of $26.22 is far below the current price, implying the stock is considerably overvalued (over 17% upside/downside misalignment). The debt‑to‑equity ratio of 276.6× and ongoing PFAS litigation add regulatory and balance‑sheet risk, while the sector’s industrial conglomerate exposure brings medium sector risk. Investors should weigh the solid cash flow and dividend against the high valuation, debt load, and regulatory headwinds when deciding on positioning.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Oversold RSI indicating potential rebound
  • Recent earnings beat and dividend declaration
  • Increasing volume supporting short‑term upside

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Significant overvaluation relative to DCF fair value
  • Strong cash flow and sustainable dividend yield
  • Elevated debt levels and pending regulatory issues

Long Term

> 3 years
Cautious
Model confidence: 5/10

Key Factors

  • Persistently high valuation without commensurate growth
  • High debt‑to‑equity ratio and PFAS litigation risk
  • Potential for continued regulatory and sector headwinds

Key Metrics & Analysis

Financial Health

Revenue Growth2.00%
Profit Margin13.03%
P/E Ratio25.6
ROE75.50%
ROA7.58%
Debt/Equity276.64
P/B Ratio17.1
Op. Cash Flow$2.3B
Free Cash Flow$1.3B
Industry P/E29.5

Technical Analysis

TrendBullish
RSI32.6
Support$147.72
Resistance$177.41
MA 20$164.94
MA 50$163.29
MA 200$158.33
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89

Valuation

Fair Value$26.22
Target Price$178.73
Upside/Downside17.87%
GradeOvervalued
TypeValue
Dividend Yield2.03%

Risk Assessment

Beta1.08
Volatility30.17%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.